Author/Authors :
Tadic, Marijana University Clinical Hospital Centre “Dr. Dragisa Misovic -Dedinje”, Serbia , Tadic, Marijana Doktora Subotica - Faculty of Medicine, Serbia , Cuspidi, Cesare University of Milan - Bicocca and Istituto AuxologicoItaliano, Clinical Research Unit, Italy , Ivanovic, Branislava Doktora Subotica - Faculty of Medicine, Serbia , Ivanovic, Branislava Clinical Center of Serbia, Clinic of Cardiology, Serbia
Abstract :
Breast cancer represents one of the most prevalent malignant diseases and also one of the most frequent causes of cancer mortality in females in the world. More than 20% of invasive breast cancers are characterized by the overexpression of human epidermal growth factor receptor type 2 (HER2), which is unfortunately related to a poor prognosis (1). The American Society of Clinical Oncology guidelines recommended the evaluation of HER2 in every invasive breast cancer, at either the time of diagnosis or recurrence, to guide therapy.
